Billings Clinic
Especially For:

Clinical Trials

Title   GI (RTOG 1010): HER2-Overexpressing Esophageal adenocarcinoma
Description   A Randomized Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment o fHER2-Overexpressing Esophageal Adenocarcinoma
IRB Number   RTOG R1010
Category   Gastrointestinal
Inclusion/Notes   Cancer that involves the mid to distal esophagus, and up to 5 cm of the stomach. T1 N1-2, T2-3 N0-1. Must have tissue available for HER2 testing by central pathology. Surgical consult confirming pt can undergo a cruative resection after completion of chemoradiation. Endoscopic ultrasound prior to step 2 registration unless patient is found to have adenopathy per scan(s).
Status   Active
Start Date   03/11/2011
Principal Investigator (PI)   John Schallenkamp, MD
Contact Name   Susan Dillon, RN
Contact Email   sdillon!@billingsclinic.org
Phone   (406) 435-7443
Fax   (406) 435-7489
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.